Pulike Biological Engineering, Inc.

Shanghai Stock Exchange 603566.SS

Pulike Biological Engineering, Inc. Price to Book Ratio (P/B) on January 27, 2025: 1.54

Pulike Biological Engineering, Inc. Price to Book Ratio (P/B) is 1.54 on January 27, 2025, a -25.76% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Pulike Biological Engineering, Inc. 52-week high Price to Book Ratio (P/B) is 3.02 on May 21, 2024, which is 96.75% above the current Price to Book Ratio (P/B).
Pulike Biological Engineering, Inc. 52-week low Price to Book Ratio (P/B) is 1.39 on September 18, 2024, which is -9.31% below the current Price to Book Ratio (P/B).
Pulike Biological Engineering, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is 1.82.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

Shanghai Stock Exchange: 603566.SS

Pulike Biological Engineering, Inc.

CEO	Mr. Wei Hu
IPO Date	May 18, 2015
Location	China
Headquarters	No.15 Zhenghe Road
Employees	1,679
Sector	Health Care
Industries Biotechnology Pharmaceuticals Vaccines

Description

Pulike Biological Engineering, Inc. engages in the research and development, production, and marketing of veterinary biological products and drugs. It offers vaccines, antibodies, and medicines for swine and poultry, as well as disinfectants. The company is headquartered in Luoyang, China.

Key trends

Past 5 years